12,375 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 12,375 shares of the biotechnology company’s stock, valued at approximately $233,000.

Other large investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $434,000. Virtu Financial LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $381,000. Magnetar Financial LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $270,000. Teacher Retirement System of Texas grew its holdings in shares of Arrowhead Pharmaceuticals by 18.3% in the fourth quarter. Teacher Retirement System of Texas now owns 33,154 shares of the biotechnology company’s stock valued at $623,000 after purchasing an additional 5,118 shares in the last quarter. Finally, Privium Fund Management B.V. increased its stake in Arrowhead Pharmaceuticals by 14.2% during the 4th quarter. Privium Fund Management B.V. now owns 380,586 shares of the biotechnology company’s stock worth $7,155,000 after buying an additional 47,230 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the sale, the chief executive officer now directly owns 3,764,252 shares of the company’s stock, valued at $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 286,317 shares of company stock worth $5,049,735 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $13.82 on Friday. The business has a 50 day moving average price of $18.13 and a 200 day moving average price of $19.62. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $13.66 and a fifty-two week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on ARWR. Sanford C. Bernstein decreased their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reissued a “buy” rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.